AI Article Synopsis

Article Abstract

Human Polycomb-group (PcG) genes play a crucial role in the regulation of embryonic development and regulation of the cell cycle and hematopoiesis. PcG genes encode proteins that form two distinct PcG complexes, involved in maintenance of cell identity and gene silencing patterns. We recently showed that expression of the BMI-1 and EZH2 PcG genes is separated during normal B-cell development in germinal centers, whereas Hodgkin/Reed-Sternberg (H/RS) cells co-express BMI-1 and EZH2. In the current study, we used immunohistochemistry and immunofluorescence to determine whether the binding partners of these PcG proteins are also present in H/RS cells and H/RS-derived cell lines. PcG expression profiles were analyzed in combination with expression of the cell cycle inhibitor p16INK4a, because experimental model systems indicate that p16 is a downstream target of Bmi-1. We found that H/RS cells and HL-derived cell lines co-express all core proteins of the two known PcG complexes, including BMI-1, MEL-18, RING1, HPH1, HPC1, and -2, EED, EZH2, YY1, and the HPC2 binding partner, CtBP. Expression of HPC1 has not been found in normal mature B cells and other malignant lymphomas of B-cell origin, suggesting that the PcG expression profile of H/RS is unique. In contrast to Bmi-1 transgenic mice where p16INK4a is down-regulated, 27 of 52 BMI-1POS cases of HL revealed strong nuclear expression of p16INK4a. We propose that abnormal expression of BMI-1 and its binding partners in H/RS cells contributes to development of HL. However, abnormal expression of BMI-1 in HL is not necessarily associated with down-regulation of p16INK4a.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1613333PMC
http://dx.doi.org/10.1016/S0002-9440(10)63175-6DOI Listing

Publication Analysis

Top Keywords

h/rs cells
16
cell lines
12
pcg genes
12
expression bmi-1
12
expression
9
pcg
8
cell cycle
8
pcg complexes
8
bmi-1 ezh2
8
binding partners
8

Similar Publications

Serotonin-2B receptor (5-HTR) expression and binding in the brain of APP/PS1 transgenic mice and in Alzheimer's disease brain tissue.

Neurosci Lett

January 2025

Department of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Department of Life Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus. Electronic address:

Despite well-documented dysregulation in central serotonergic signaling in Alzheimer's disease (AD), knowledge about the potential involvement of the serotonin-2B receptor (5-HTR) subtype remains sparse. Here, we assessed the levels of 5-HTRs in brain tissue from APP/PS1 transgenic (TG) mice, AD patients, and adult microglial cells. 5-HTR mRNA was measured by RT-qPCR in ageing TG and wild-type (WT) mice, in samples from the middle frontal gyrus of female, AD and control subjects, and in microglia from the cerebral cortex of WT mice.

View Article and Find Full Text PDF

Autoantibodies targeting the neuronal antigen metabotropic glutamate receptor 5 (mGluR5) have been identified in patients with Ophelia syndrome, which describes a co-occurrence of paraneoplastic limbic encephalitis and Hodgkin lymphoma (HL). Little data exist regarding frequency and function of mGluR5 in HL and its potential role in causing seropositive paraneoplastic disease. We studied a representative cohort of pediatric HL and NHL patients (n = 57) using immunohistochemistry and fluorescence staining to investigate mGluR5 expression.

View Article and Find Full Text PDF

This is the first autopsy case of Epstein-Barr virus-positive marginal zone lymphoma (EBV + MZL) with an other iatrogenic immunodeficiency-associated lymphoproliferative disorders (LPD) (methotrexate [MTX]-associated LPD) that deteriorated after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. This case had a unique immunophenotype. A 71-year-old female patient with rheumatoid arthritis receiving MTX presented with fatigue 1 week after the SARS-CoV-2 vaccination.

View Article and Find Full Text PDF
Article Synopsis
  • Classical Hodgkin lymphoma (CHL) is usually treatable, but 15-25% of patients may relapse and face a higher risk of death from the disease.
  • The study analyzed the cellular microenvironment in CHL patients, comparing those responding well to treatment (RESP) with those experiencing relapses or refractory disease (REL).
  • Findings revealed increased levels of specific macrophages, PDL-1 cells, and microvessels in REL patients, alongside a decrease in certain lymphocytes, highlighting potential targets for immunotherapy.
View Article and Find Full Text PDF

A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of huntington's disease.

BMB Rep

March 2023

Department of Biomedical Science, CHA University, Seongnam 13488; iPS Bio Inc., Seongnam 13488, Korea.

Huntington's disease (HD) is a neurodegenerative disorder, of which pathogenesis is caused by a polyglutamine expansion in the amino-terminus of huntingtin gene that resulted in the aggregation of mutant HTT proteins. HD is characterized by progressive motor dysfunction, cognitive impairment and neuropsychiatric disturbances. Histone deacetylase 6 (HDAC6), a microtubule-associated deacetylase, has been shown to induce transport- and release-defect phenotypes in HD models, whilst treatment with HDAC6 inhibitors ameliorates the phenotypic effects of HD by increasing the levels of α-tubulin acetylation, as well as decreasing the accumulation of mutant huntingtin (mHTT) aggregates, suggesting HDAC6 inhibitor as a HD therapeutics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!